Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of survodutide in adults with non-cirrhotic MASH/NASH and fibrosis
CTR20244844Phase 3Active
- Sponsor
- ——/ 勃林格殷格翰(中国)投资有限公司
- Start
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Survodutide with Placebo (2 arms). Primary endpoints: MASH resolution without worsening of liver fibrosis, At least 1-stage fibrosis improvement without worsening of MASH and 1 more. Started Jul 2025; status: active.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20244844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244844.